National Institutes of Health

New Hope for Treatment-Resistant Depression: Guessing Right on Ketamine

In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.

Ketamine and Depression: From Despair to Hope in Hours

Carlos Zarate, M.D., speeds up treatment for major depression at the National Institutes of Health (NIH) Intramural Research Program (IRP). Dr. Zarate is Chief of the Experimental Therapeutics & Pathophysiology Branch and the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health (NIMH).

Scroll to Top